Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03371758

Enrollment

Registered

2017-12-13

Start date

2017-01-31

Completion date

2018-05-31

Last updated

2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autophagy

Brief summary

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Interventions

OTHERskin biopsy

Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* • Patients with non-segmental vitiligo whether active or stable. * Age above 12 years. * Both sexes.

Exclusion criteria

* • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study. * Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease. * Pregnancy or breast feeding for female patients.

Design outcomes

Primary

Measure	Time frame
Expression of LC3-I, LC3-II & Beclin 1 in vitiligo patients	1 year

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026